---
layout: post
title: About me
author: Ke Yi
tags: [resume]
date: 2023-10-12 11:19 +0800
last_modified_at: 2023-11-15 18:35 +0800
toc: true
---

# <i class="fa-solid fa-id-card"></i> Ke Yi

<i class="fa-solid fa-location-dot"></i> Guangzhou, P. R. China

<i class="fa-solid fa-phone"></i> Tel: +86-135-4796-0573


<i class="fa-solid fa-envelope"></i> mail: keyi26@outlook.com

## 1. About
<i class="fa-solid fa-dna"></i> Powerful theoretical knowledge and skills in **CRISPR/Cas** gene editing with system construction

<i class="fa-solid fa-disease"></i> Senior experience in **cancer immunotherapy**, including **messenger RNA synthesis and delivery, T cell engineering, and adoptive T cell therapy**

<i class="fa-solid fa-flask-vial"></i> Extensive experience in synthesis and optimization of **liposomes, polymeric nanoparticles, and magnetic nanoparticles**

## 2. Education

### Sichuan University
<i class="fa-solid fa-location-dot"></i> Chengdu, P. R. China

<i class="fa-solid fa-clock"></i> 2015.09 ~ 2019.06

<i class="fa-solid fa-graduation-cap"></i> B.S in Biological Science

### Sun Yat-sen University
<i class="fa-solid fa-location-dot"></i> Guangzhou, P. R. China

<i class="fa-solid fa-clock"></i> 2019.06 ~ 2024.06

<i class="fa-solid fa-graduation-cap"></i> Ph.D in Basic Medicine (Molecular Medicine)

- Liposomes for combination cancer therapy of **CRISPR/Cas systems** and tyrosine kinase inhibitors
- **Adoptive cell immunotherapy** based on liposome-engineered T cell for solid tumor treatment

## 3. Skills
### Experimental skills

<i class="fa-solid fa-flask-vial"></i> **Materials:** Preparation of liposomes, polymeric nanoparticles, and magnetic nanoparticles

<i class="fa-solid fa-dna"></i>  **Molecular Biology:** Construction of CRISPR/Cas systems, Synthesis of IVT mRNA, RT-qPCR, Western blot, ELISA

<i class="fa-solid fa-table-cells"></i> **Cell Biology:** Cell culture, Cell transfection, extraction and expansion of primary T cells, flow cytometry, fluorescence microscopy

<i class="fa-solid fa-capsules"></i> ***In vivo* drug administration:** Intravenous, subcutaneous and intraperitoneal injections, gavage, and in situ implantation of biomaterials (nanofiber meshes, 3D-printed scaffolds, and hydrogels) on liver

<i class="fa-solid fa-disease"></i> **Establishing Tumor-bearing mouse models：** subcutaneous melanoma/prostate cancer/hepatic cell carcinoma (HCC) model, and orthotopic HCC Model


## 4. Honor
<i class="fa-solid fa-award" style="color: #f7be22;"></i> 2023, National Scholarship for Ph.D. Students in China

<i class="fa-solid fa-award" style="color: #f7be22;"></i> 2019 & 2021, 2nd-class Scholarship for Ph.D. Students at Sun Yat-sen University

## 5. Publication
### (1). First Author and Co-first Author (†)
1. **<u>Yi, K.</u>**†, Kong, H.†, Lao, Y.-H.†, Li, D., Mintz, R.L., Fang, T., Chen, G., Tao, Y., Li, M., Ding, J., 2023. Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy. Adv. Mater. e2300665. https://doi.org/10.1002/adma.
1. **<u>Yi, K.</u>**, Kong, H., Zheng, C., Zhuo, C., Jin, Y., Zhong, Q., Mintz, R.L., Ju, E., Wang, H., Lv, S., Lao, Y.-H., Tao, Y., Li, M., 2023. A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy. Biomaterials 122349. https://doi.org/10.1016/j.biomaterials.2023.122349
1. Wei, H.†, **<u>Yi, K.</u>**†, Li, F., Li, D., Yang, J., Shi, R., Jin, Y., Wang, H., Ding, J., Tao, Y., Li, M., n.d. Multimodal Tetrahedral DNA Nanoplatform for Surprisingly Rapid and Significant Treatment of Acute Liver Failure. Advanced Materials n/a, 2305826. https://doi.org/10.1002/adma.202305826
1. Guan, Y.†, Yao, W.†, **<u>Yi, K.</u>**†, Zheng, C., Lv, S., Tao, Y., Hei, Z., Li, M., 2021. Nanotheranostics for the Management of Hepatic Ischemia-Reperfusion Injury. Small 17, 2007727. https://doi.org/10.1002/smll.202007727
1. Kong, H.†, Ju, E.†, **<u>Yi, K.</u>**†, Xu, W., Lao, Y.-H., Cheng, D., Zhang, Q., Tao, Y., Li, M., Ding, J., 2021. Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma. Adv. Sci. 8, 2102051. https://doi.org/10.1002/advs.202102051
1. Li, F.†, Zhang, J.†, **<u>Yi, K.</u>**†, Wang, H., Wei, H., Chan, H.F., Tao, Y., Li, M., 2022. Delivery of Stem Cell Secretome for Therapeutic Applications. ACS applied bio materials 5, 2009–2030. https://doi.org/10.1021/acsabm.1c01312

### （2）Co-author
1. Tao, Y., **<u>Yi, K.</u>**, Wang, H., Kim, H.-W., Li, K., Zhu, X., Li, M., 2022. CRISPR-Cas12a-regulated DNA adsorption and metallization on MXenes as enhanced enzyme mimics for sensitive colorimetric detection of hepatitis B virus DNA. J Colloid Interface Sci 613, 406–414. https://doi.org/10.1016/j.jcis.2022.01.038
1. Tao, Y., **<u>Yi, K.</u>**, Hu, H., Shao, D., Li, M., 2021. Coassembly of nucleus-targeting gold nanoclusters with CRISPR/Cas9 for simultaneous bioimaging and therapeutic genome editing. Journal of Materials Chemistry. B Online ahead of print. https://doi.org/10.1039/d0tb01925a
1. Dang, W., **<u>Yi, K.</u>**, Ju, E., Jin, Y., Xu, Y., Wang, H., Chen, W.-C., Wang, K., Wang, Y., Tao, Y., Li, M., 2021b. 3D Printed Bioceramic Scaffolds as a Universal Therapeutic Platform for Synergistic Therapy of Osteosarcoma. ACS Applied Materials \& Interfaces 13, 18488–18499. https://doi.org/10.1021/acsami.1c00553
1. Tao, Y., **<u>Yi, K.</u>**, Wang, H., Li, K., Li, M., 2022b. Metal nanoclusters combined with CRISPR-Cas12a for hepatitis B virus DNA detection. Sensors and Actuators B-Chemical 361, 131711. https://doi.org/10.1016/j.snb.2022.131711
1. Kong, H., **<u>Yi, K.</u>**, Zheng, C., Lao, Y.-H., Zhou, H., Chan, H.F., Wang, H., Tao, Y., Li, M., 2022. Membrane-fusogenic biomimetic particles: a new bioengineering tool learned from nature. J. Mater. Chem. B 10, 6841–6858.https://doi.org/10.1039/D2TB00632D
1. Dang, W., Jin, Y., **<u>Yi, K.</u>**, Ju, E., Zhuo, C., Wei, H., Wen, X., Wang, Y., Li, M., Tao, Y., 2021a. Hemin particles-functionalized 3D printed scaffolds for combined photothermal and chemotherapy of osteosarcoma. Chem. Eng. J. 422, 129919. https://doi.org/10.1016/j.cej.2021.129919
1. Jin, Y., Wang, H., **<u>Yi, K.</u>**, Lv, S., Hu, H., Li, M., Tao, Y., 2021. Applications of Nanobiomaterials in the Therapy and Imaging of Acute Liver Failure. Nano-micro Lett. 13, 25. https://doi.org/10.1007/s40820-020-00550-x
1. Tao, Y., Lao, Y.-H., **<u>Yi, K.</u>**, Xu, Y., Wang, H., Shao, D., Wang, J., Li, M., 2021a. Noble metal-molybdenum disulfide nanohybrids as dual fluorometric and colorimetric sensor for hepatitis B virus DNA detection. Talanta 234, 122675. https://doi.org/10.1016/j.talanta.2021.122675
1. Zheng, C., Zhong, Q., **<u>Yi, K.</u>**, Kong, H., Cao, F., Zhuo, C., Xu, Y., Shi, R., Ju, E., Song, W., Tao, Y., Chen, X., Li, M., 2023b. Anti-phagocytosis-blocking repolarization-resistant membrane-fusogenic liposome (ARMFUL) for adoptive cell immunotherapy. Sci. Adv. 9, eadh2413. https://doi.org/10.1126/sciadv.adh2413
1. Zhong, Q., Zheng, C., **<u>Yi, K.</u>**, Mintz, R.L., Lv, S., Tao, Y., Li, M., 2023. Structural and componential design: new strategies regulating the behavior of lipid-based nanoparticles in vivo. Biomater. Sci. 11, 4774–4788. https://doi.org/10.1039/d3bm00387f
1. Zhuo, C., Kong, H., **<u>Yi, K.</u>**, Chi, C.-W., Zhang, J., Chen, R., Wang, H., Wu, C., Lao, Y.-H., Tao, Y., Li, M., 2023. Magnetic-Activated Nanosystem with Liver-Specific CRISPR Nonviral Vector to Achieve Spatiotemporal Liver Genome Editing as Hepatitis B Therapeutics. Adv. Funct. Mater. 33, 2210860. https://doi.org/10.1002/adfm.202210860
1. Zheng, C., Zhong, Q., Song, W., **<u>Yi, K.</u>**, Kong, H., Wang, H., Tao, Y., Li, M., Chen, X., 2023a. Membrane-Fusion-Mediated Multiplex Engineering of Tumor Cell Surface Glycans for Enhanced NK Cell Therapy. Adv. Mater. n/a, 2206989. https://doi.org/10.1002/adma.202206989
1. Jin, Y., Zhang, J., Xu, Y., **<u>Yi, K.</u>**, Li, F., Zhou, H., Wang, H., Chan, H.F., Lao, Y.-H., Lv, S., Tao, Y., Li, M., 2023. Stem cell-derived hepatocyte therapy using versatile biomimetic nanozyme incorporated nanofiber-reinforced decellularized extracellular matrix hydrogels for the treatment of acute liver failure. Bioactive Materials 28, 112–131. https://doi.org/10.1016/j.bioactmat.2023.05.001
1.  Qin, Y., Lao, Y.-H., Wang, H., Zhang, J., **<u>Yi, K.</u>**, Chen, Z., Han, J., Song, W., Tao, Y., Li, M., 2021. Combatting Helicobacter pylori with oral nanomedicines. J. Mater. Chem. B 9, 9826–9838. https://doi.org/10.1039/d1tb02038b

## 6. Conference presentations
1. **Poster Presnetation:** A LIGHTFUL Nanomedicine Overcomes EGFR-Mediated Drug Resistance for Enhanced Tyrosine-Kinase-Inhibitor-Based Hepatocellular Carcinoma Therapy. **The 5th Annual Meeting of Chinese American Society of Nanomedicine and Nanobiotechnology.** Guangzhou, China, 2023.

## 7. Patent
1. Li M., Tao Y., **<u>Yi, K.</u>**, Kong H., Package (Membrabane-fusogenic liposome-based transfection reagent), 202230741460.5, Chinese Appearance Patent, 2023, authorized.
1. Li M., Tao Y., **<u>Yi, K.</u>**, Zhuo C., Package (Magnetic nanoparticle-based transfection reagent), 202230740676.X, Chinese Appearance Patent, 2023, authorized.
1. Li M., Tao Y., **<u>Yi, K.</u>**, Zhuo C., Kong H., Package (liver-specific gene-editing plasmid), 202230741458.8., Chinese Appearance Patent, 2023, authorized.
1. Li M., Tao Y., **<u>Yi, K.</u>**, Kong H., Zheng C., Zhuo C., Synthesis and application of a gene-editing nanodrug to overcome drug-resistance of tumor, 2023106238489, Chinese Invention Patent, submitted.
1. Li M., Kong H., Zheng C., **<u>Yi, K.</u>**, Tao Y., Synthesis and application of an antifouling membrane-fusogenic nanovector, 2023106237787, Chinese Invention Patent, submitted.
1. Li M., Tao Y., Kong H., Zhuo C., **<u>Yi, K.</u>**, Zheng C., Zhong Q., Synthesis and application of a gene-editing nanovector, 202210130435.2, Chinese Invention Patent, submitted.
1. Li M., Tao Y., Zhuo C., Kong H., **<u>Yi, K.</u>**, Dang W., Synthesis and application of a liver-specific gene-editing nanovedrug, 202210094797.0, Chinese Invention Patent, submitted.